0001493152-23-033779.txt : 20230926 0001493152-23-033779.hdr.sgml : 20230926 20230926173428 ACCESSION NUMBER: 0001493152-23-033779 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230922 FILED AS OF DATE: 20230926 DATE AS OF CHANGE: 20230926 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tapolczay David CENTRAL INDEX KEY: 0001991789 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41245 FILM NUMBER: 231281400 MAIL ADDRESS: STREET 1: 32 CROUCH HALL LANE CITY: ST. ALBANS STATE: X0 ZIP: AL3 7EU ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CONDUIT PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001896212 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 873272543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4995 MURPHY CANYON ROAD, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92123 BUSINESS PHONE: (760) 471 8536 MAIL ADDRESS: STREET 1: 4995 MURPHY CANYON ROAD, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92123 FORMER COMPANY: FORMER CONFORMED NAME: Murphy Canyon Acquisition Corp. DATE OF NAME CHANGE: 20211130 3 1 ownership.xml X0206 3 2023-09-22 0 0001896212 CONDUIT PHARMACEUTICALS INC. CDT 0001991789 Tapolczay David 4995 MURPHY CANYON ROAD, SUITE 300 SAN DIEGO CA 92123 1 1 0 0 Chief Executive Officer Common Stock, par value $0.0001 per share 2003324 D Includes 2,003,324 shares of common stock of the Company received pursuant to the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023, by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc." /s/ David Tapolczay 2023-09-26